Hansa Biopharma AB has appointed Maria Törnsén as Chief Operating Officer (COO) and President U.S., effective May 19.

She will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.

Experience

Törnsén has more than 20 years of experience across global and U.S. operations, where she held multiple senior commercial leadership roles. Most recently, she held the position of President North America at Calliditas Therapeutics, where she was responsible for the US commercial and medical affairs organization, until it was acquired by Asahi Kasei Corporation in September 2024.

Previously, Törnsén held senior leadership and commercial leadership roles at Sarepta Therapeutics, Sanofi Genzyme, and Shire plc. During her career, she has launched multiple products in the U.S. and led a $ 1.6 billion global franchise.

Törnsén is a member of the board of directors of Immunic Therapeutics and has a Master of Science (MSc) in International Business Administration from Lund University, Sweden. 

“We are pleased to welcome Törnsén to the executive management team as COO and President of the U.S. business,” said CEO Renée Aguiar-Lucander. “She brings invaluable experience in the area of rare diseases and gene therapy, from building commercial organizations, launching new products, and driving growth and profitability, which will be critical as we prepare for the next phase of our development.”

“I am delighted to join Hansa at this exciting time in the company’s history. I look forward to working with the Hansa team and leveraging my experience from prior roles to support the continued growth of IDEFIRIX and prepare for multiple anticipated catalysts in the second half of 2025,” said Törnsén.